Coviden, Siemens combine SPECT, PET radioisotope portfolios
Covidien, a provider of healthcare products, and PETNET Solutions, a wholly owned subsidiary of Siemens Medical Solutions, have entered into a co-marketing agreement to offer a combined portfolio of high-energy and low-energy radioisotopes to the nuclear medicine community in the United States.  

Through the agreement, Covidien Imaging Solutions and PETNET will create a network of nuclear imaging product offerings, including molecular imaging agents, or radiopharmaceuticals, designed to illuminate conditions, such as cancer or heart disease, during imaging procedures. The agreement brings together Covidien’s SPECT products and PETNET’s PET products.

Steve Hanley, president, Covidien Imaging, said that with the agreement, the company is positioned to offer its nuclear medicine customers expanded access to both product lines to help them provide better patient diagnostic services. It will also provide PETNET with access to its SPECT product offerings.

PETNET operates a large PET radiopharmacy network with more than 44 radiopharmacies and distribution centers, which produce and distribute PET radiopharmaceuticals to hospitals, clinics and research facilities for PET imaging.